The company recently obtained approval from the US Food and Drug Administration (FDA) for Cyclo G6 system to treat patients with a wide range of glaucoma disease states.

IRIDEX president and CEO Will Moore said: "Our proprietary Cyclo G6 platform allows IRIDEX to participate in both hardware and the faster growing procedural side of the glaucoma market, representing a new and more predictable recurring revenue stream.

"The cost and logistics of administering glaucoma medications is a burden to both the patient and healthcare organizations; furthermore, patients using prescribed medications have a poor record of compliance."

The system features firm’s MicroPulse tissue-sparing technology and a family of single use probes, which connect to the user-friendly laser console.

According to the company, MicroPulse provides a repeatable and minimally invasive approach to reduce the progress of the disease and elimination the need for invasive surgical intervention.

At the event, the company will also make a scientific poster presentation entitled, "MicroPulse Trans-scleral Cyclophotocoagulation (mTSCPC) for the Treatment of Glaucoma using the MicroPulse P3 Device," featuring results from early clinical application of the new MicroPulse P3 disposable.

Established in 1989, IRIDEX develops and markets laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market.